Filing Details

Accession Number:
0001127602-21-005607
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-16 08:45:00
Reporting Period:
2021-02-11
Accepted Time:
2021-02-16 08:45:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
794172 Meridian Bioscience Inc VIVO In Vitro & In Vivo Diagnostic Substances (2835) 310888197
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1719325 P. John Kenny 3471 River Hills Drive
Cincinnati OH 45244
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-11 1,164 $10.10 253,340 No 4 M Direct
Common Stock Disposition 2021-02-11 1,320 $30.00 252,020 No 4 S Direct
Common Stock Acquisiton 2021-02-12 23,097 $10.10 275,117 No 4 M Direct
Common Stock Disposition 2021-02-12 26,181 $30.14 248,936 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2021-02-11 1,164 $0.00 1,164 $10.10
Common Stock Stock Options (Right to Buy) Disposition 2021-02-12 23,097 $0.00 23,097 $10.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
180,821 2029-11-05 No 4 M Direct
157,724 2029-11-05 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020.
  2. Prices range from $30.00 per share to $30.015 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
  3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020.
  4. Prices range from $30.00 per share to $30.49 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
  5. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020.
  6. These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date.
  7. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020.